Critical Review: Sagimet Biosciences (NASDAQ:SGMT) and Pluri (NASDAQ:PLUR)

Sagimet Biosciences (NASDAQ:SGMT) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Valuation & Earnings

This table compares Sagimet Biosciences and Pluri”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2.00 million	338.15	-$51.04 million	($1.28)	-8.50
Pluri	$1.02 million	14.88	-$23.82 million	($4.53)	-0.27

Pluri has lower revenue, but higher earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sagimet Biosciences has a beta of 3.45, indicating that its share price is 245% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Institutional & Insider Ownership

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by insiders. Comparatively, 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Sagimet Biosciences and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Pluri	-2,344.59%	N/A	-82.71%

Analyst Recommendations

This is a summary of recent recommendations for Sagimet Biosciences and Pluri, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1	1	9	0	2.73
Pluri	1	0	0	0	1.00

Sagimet Biosciences presently has a consensus price target of $27.96, indicating a potential upside of 156.97%. Given Sagimet Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Sagimet Biosciences is more favorable than Pluri.

Summary

Sagimet Biosciences beats Pluri on 10 of the 14 factors compared between the two stocks.

About Sagimet Biosciences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.